Mouse Glioma Immunotherapy Mediated by A2B5+ GL261 Cell Lysate-pulsed Dendritic Cells

Overview

Journal J Neurooncol

Publisher Springer

Date 2014 Jan 9

PMID 24398615

Citations 17

Authors

Ming Xu

Yu Yao

Wei Hua

Zhebao Wu

Ping Zhong

Ying Mao

Liangfu Zhou

Feifei Luo

Yiwei Chu

Affiliations

Soon will be listed here.

Abstract

Immunotherapy strategies targeting glioma stem-like cells (GSCs) hold promise for improving outcomes in glioblastoma patients. We used the A2B5 monoclonal antibody to classify GSCs derived from the mouse GL261 glioma cell line, and A2B5+ GL261 cell lysate-pulsed dendritic cells (DCs) were used to treat mouse glioma. We found that such DCs elicited a stronger specific cytotoxic T lymphocyte response against A2B5+ GL261 cells than A2B5- GL261 cell lysate-pulsed DCs. The effect of A2B5+ GL261 cell lysate-pulsed DCs in vivo depended on when the vaccination was started. In the tumor cell adaptation phase, C57BL/6 mice had an immune response against GL261, and vaccination enhanced the immune response and prevented glioma formation in 37.5% of mice. In contrast, after glioma formation, the immune response against GL261 was decreased, and vaccination had no therapeutic effect. Our findings suggest that vaccination with A2B5+ GL261 cell lysate-pulsed DCs only has some glioma preventive effect.

Citing Articles

A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.

Sferruzza G, Consoli S, Dono F, Evangelista G, Giugno A, Pronello E Neurol Sci. 2024; 45(6):2561-2578.

PMID: 38308708 DOI: 10.1007/s10072-024-07350-w.

Tumor microenvironment of cancer stem cells: Perspectives on cancer stem cell targeting.

Guo Q, Zhou Y, Xie T, Yuan Y, Li H, Shi W Genes Dis. 2024; 11(3):101043.

PMID: 38292177 PMC: 10825311. DOI: 10.1016/j.gendis.2023.05.024.

Combination of DNA Vaccine and Immune Checkpoint Blockades Improves the Immune Response in an Orthotopic Unresectable Glioblastoma Model.

Bausart M, Vanvarenberg K, Ucakar B, Lopes A, Vandermeulen G, Malfanti A Pharmaceutics. 2022; 14(5).

PMID: 35631612 PMC: 9145362. DOI: 10.3390/pharmaceutics14051025.

A2B5 Expression in Central Nervous System and Gliomas.

Figarella-Branger D, Colin C, Baeza-Kallee N, Tchoghandjian A Int J Mol Sci. 2022; 23(9).

PMID: 35563061 PMC: 9103745. DOI: 10.3390/ijms23094670.

Immunotherapy for glioblastoma: the promise of combination strategies.

Bausart M, Preat V, Malfanti A J Exp Clin Cancer Res. 2022; 41(1):35.

PMID: 35078492 PMC: 8787896. DOI: 10.1186/s13046-022-02251-2.

References

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Hua W, Yao Y, Chu Y, Zhong P, Sheng X, Xiao B . The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma. J Neurooncol. 2011; 105(2):149-57. DOI: 10.1007/s11060-011-0572-y. View

Maes W, Van Gool S . Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother. 2010; 60(2):153-60. PMC: 11028904. DOI: 10.1007/s00262-010-0946-6. View

Grauer O, Sutmuller R, van Maren W, Jacobs J, Bennink E, Toonen L . Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer. 2007; 122(8):1794-802. DOI: 10.1002/ijc.23284. View

Wu A, Oh S, Wiesner S, Ericson K, Chen L, Hall W . Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev. 2008; 17(1):173-84. DOI: 10.1089/scd.2007.0133. View

Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T . Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401. DOI: 10.1038/nature03128. View

Woolard K, Fine H . Glioma stem cells: better flat than round. Cell Stem Cell. 2009; 4(6):466-7. DOI: 10.1016/j.stem.2009.05.013. View

Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber E, Kohanbash G . Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res. 2009; 15(21):6551-9. PMC: 2783346. DOI: 10.1158/1078-0432.CCR-09-1067. View

Prins R, Odesa S, Liau L . Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 2003; 63(23):8487-91. View

10.

Szatmari T, Lumniczky K, Desaknai S, Trajcevski S, Hidvegi E, Hamada H . Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 2006; 97(6):546-53. PMC: 11159227. DOI: 10.1111/j.1349-7006.2006.00208.x. View

11.

Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir I . Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006; 5:67. PMC: 1697823. DOI: 10.1186/1476-4598-5-67. View

12.

Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S . Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004; 64(19):7011-21. DOI: 10.1158/0008-5472.CAN-04-1364. View

13.

Wei J, Barr J, Kong L, Wang Y, Wu A, Sharma A . Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res. 2010; 16(2):461-73. PMC: 2943842. DOI: 10.1158/1078-0432.CCR-09-1983. View

14.

Son M, Woolard K, Nam D, Lee J, Fine H . SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009; 4(5):440-52. PMC: 7227614. DOI: 10.1016/j.stem.2009.03.003. View

15.

Hatiboglu M, Wei J, Wu A, Heimberger A . Immune therapeutic targeting of glioma cancer stem cells. Target Oncol. 2010; 5(3):217-27. PMC: 4262967. DOI: 10.1007/s11523-010-0151-8. View

16.

Maes W, Deroose C, Reumers V, Krylyshkina O, Gijsbers R, Baekelandt V . In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma. J Neurooncol. 2008; 91(2):127-39. DOI: 10.1007/s11060-008-9691-5. View

17.

Finn O . Cancer immunology. N Engl J Med. 2008; 358(25):2704-15. DOI: 10.1056/NEJMra072739. View

18.

Ksendzovsky A, Feinstein D, Zengou R, Sharp A, Polak P, Lichtor T . Investigation of immunosuppressive mechanisms in a mouse glioma model. J Neurooncol. 2009; 93(1):107-14. DOI: 10.1007/s11060-009-9884-6. View

19.

Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner P . CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007; 67(9):4010-5. DOI: 10.1158/0008-5472.CAN-06-4180. View

20.

Jedema I, van der Werff N, Barge R, Willemze R, Falkenburg J . New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood. 2003; 103(7):2677-82. DOI: 10.1182/blood-2003-06-2070. View